133-140 Asli Cakar - Hacettepe Üniversitesi Tıp Fakültesi

Çakar ve Özkuyumcu
13. Verhage M, Toonen R. Regulated exocytosis: merging ideas
on fusing membranes. Curr Opin Cell Biol 2007; 19:402-8.
14. Giraudo CG, Garcia-Diaz A, Eng WS, Chen Y, Hendrickson
WA. Alternative Zippering as an on-off switch for SNAREmediated
fusion. Science 2009; 323:512-6.
15. Rickman C, Davletov B. Mechanism of calcium-independent
synaptotagmin binding to target SNAREs. J Biol Chem
2003; 278:5501-4.
16. Burgoyne R, Barclay JW, Ciufo L, Graham M, Handley M,
Morgan A. The functions of Munc18-1 in regulated exocytosis.
Ann NY Acad Sci 2009; 1152:76-86.
17. Hay J. SNARE complex structure and function. Exp Cell Res
2001; 271:10-21.
18. Sun W, Yan Q, Vida T, Bean AJ. Hrs regulates early endosome
fusion by inhibiting formation of an endosomal SNARE
complex. J Cell Biol 2003; 162:125-37.
19. Ludger J, Galli T. Exocytosis: SNAREs drum up. Eur J Neurosci
1998; 10:415-22.
20. Cai H, Reim K, Varoqueaux F, Tapechum S, Hill K, Sorensen
JB, et al. Complexin II plays a positive role in Ca2+-triggered
exocytosis by facilitating vesicle priming. PNAS 2008;
105:19538-43.
21. Maximov A, Tang J, Yang X, Pang Z, Südhof TC. Complexin
controls the force transfer from SNARE complexes to
membranes in fusion. Science 2009; 323:516-21.
22. Whelchel D, Brehmer TM, Brooks P, Darragh N, Coffield JA.
Molecular targets of botulinum toxin at the mammalian
neuromuscular junction. Mov Dis 2004; 19:7-16.
23. Rosetto O, Seveso M, Caccin P, Schiavo G, Montecucco C.
Tetanus and botulinum neurotoxins: turning bad guys into
good by research. Toxicon 2001; 39:27-41.
24. Humeau Y, Doussau F, Grant N, Poulain B. How botulinum
and tetanus neurotoxins block neurotransmitter release. Biochimie
2000; 82:427-46.
25. Brunger AT, Jin R, Breidenbach MA. Highly specific interactions
between botulinum neurotoxins and synaptic vesicle
proteins. Cell Mol Life Sci 2008; 65:2296-306.
26. Montecucco C, Rosetto O, Schiavo G. Presynaptic receptor
arrays for clostridial neurotoxins. Trends in Microbiol
2004; 12:442-6.
27. Rossetto O, Rigoni M, Montecucco C. Different mechanism
of blockade of neuroexocytosis by presynaptic neurotoxins.
Toxicology Letters 2004; 149:91-101.
28. Tsukamato K, Kozai Y, Ihara H, Kodha T, Mukamoto M, Tsuji
T, et al. Identification of the receptor-bindingsites in carboxyl-terminal
half of the heavy chain of botulinum neurotoxin
types C and D. Microbial Pathogenesis 2008;
44:484-93.
29. Rigoni M, Caccin P, Johnson E, Montecucco C, Rosetto O.
Site-directed mutagenesis identifies active-site residues of
the light chain of botulinum neurotoxin type A. Biochem
Biophys Res Commun 2001; 288:1231-7.
30. Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco
C, Matteoli M. Internalization and mechanism of action of
clostridial toxins in neurons. NeuroToxicology 2005;
26:761-7.
31. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR. Is
the light chain subcellular localization an important factor
in botulinum toxin duration of action? Mov Disorders
2004; 19:23-34.
32. Baldwin M, Barbieri J. Associstion of botulinum neurotoxin
serotypes A and B with synaptic vesicle protein complexes.
Biochem 2007; 46:3200-10.
33. Foran P, Davletov B, Meunier FA. Getting muscles moving
again after botulinum toxin: novel therapeutic challenges.
Trends Mol Med 2003; 9:291-9.
34. Brunger A, Rummel A. Receptor and sustrate interactions of
clostridial neurotoxins. Toxicon 2009; 1-11.
35. Chen S, Hall C, Barbieri J. Substrate recognition of VAMP-2
by botulinum neurotoxin B and tetanus neurotoxin. J Biol
Chem 2008; 283:21153-9.
36. Bajohrs M, Rickman C, Binz T, Davletov B. A molecular basis
underlying differences in the toxicity of botulinum serotypes
A and E. EMBO reports 2004; 5:1090-5.
37. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence
GW, Johnson E, et al. Evaluation of the therapeutic usefulness
of botulinum neurotoxin B, C1, E, and F compared
with the long lasting type A. Basis for distinct durations of
inhibition of exocytosis in central neurons. J Biol Chem
2003; 278:1363-71.
38. Chen S, Kim J, Barbieri JT. Mechanism of substrate recognition
by botulinum neurotoxin serotype A. J Biol Chem
2007; 282:9621-7.
39. Chen S, Barbieri JT. Multiple pocket recognition of SNAP 25
by botulinum neurotoxin serotype E. J Biol Chem 2007;
282:25540-7.
40. Bajohrs M, Rickman C, Binz T, Davletov B. A molecular basis
underlying differences in the toxicity of botulinum serotype
A and E. EMBO 2004; 5:1090-95.
41. Chen S, Barbieri JT. Unique substrate recognition by botulinum
neurotoxins serotypes A and E. J Biol Chem 2006;
281:10906-11.
42. Rickman C, Meunier F, Binz T, Davletov B. High affinity interaction
of syntaxin and SNAP-25 on the plasma membrane
is abolished by Botulinum toxin E. J Biol Chem 2004;
279:644-51.
43. Delevoye C, Nilges M, Dautry-Varsat A, Subtil A. Conservation
of the biochemical properties of Inc A from Chlamydia
trachomatis and Chlamydia caviae. J Biol Chem.
2004;279:46896-906.
44. Paumet F, Weselowski J, Garcia-Diaz A, Delevoye C, Aulner
N, Schuman H, et al. Intracellular bacteria encode inhibitory
SNARE-like proteins. Plos One 2009; 4:e7375.
45. Delevoye C, Nilges M, Dehoux P, Paumet F, Perrinet S, Dautry-Varsat
A, et al. SNARE protein mimicry by an intracellular
bacterium. Plos Pathogens 2008; 4:e1000022.
46. de Felipe K, Glover R, Charpentier X, Anderson O, Reyes M,
Pericone C, et al. Legionella eukaryotic-like type IV substrates
interfere with organelle trafficking. Plos Pathogens
2008; 4:e1000117.
47. Söllner TH. Intracellular and viral membrane fusion: a uniting
mechanism. Curr Opin Cell Biol 2004; 16:429-35.
48. Shekel JJ, Wiley DC. Coiled coils in both ıntracellular vesicle
and viral membrane fusion. Cell 1998; 95:871-4.
49. Bossis I, Roden R, Gambhira R, Yang R, Tagaya M, Howley
P, et al. Interaction of tSNARE Syntaxin 18 with the Papillomavirus
minor capsid protein mediates infection. J Virol
2005; 79:6723-31.
50. Laniosz V, Nguyen C, Meneses P. Bovine Papillomavirus
Type 1 infection is mediated by SNARE Syntaxin 18. J Virol
2007; 81:7435-48.
140
H ACETTEPE T IP D ERG‹S‹